{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:51:35Z","timestamp":1793040695735,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,2,27]],"date-time":"2011-02-27T00:00:00Z","timestamp":1298764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s00702-011-0614-9","type":"journal-article","created":{"date-parts":[[2011,2,26]],"date-time":"2011-02-26T17:43:31Z","timestamp":1298742211000},"page":"1329-1333","source":"Crossref","is-referenced-by-count":42,"title":["Elevation of total homocysteine levels in patients with Parkinson\u2019s disease treated with duodenal levodopa\/carbidopa gel"],"prefix":"10.1007","volume":"118","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Jugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ebersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunar","family":"Bengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Muhlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Klostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,27]]},"reference":[{"key":"614_CR1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.euroneuro.2010.04.010","volume":"20","author":"A Antonini","year":"2010","unstructured":"Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR (2010) Levodopa and 3-OMD levels in Parkinson patients treated with duodopa. Eur Neuropsychopharmacol 20:683\u2013687","journal-title":"Eur Neuropsychopharmacol"},{"key":"614_CR2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/phrs.1997.0145","volume":"35","author":"P Benetello","year":"1997","unstructured":"Benetello P, Furlanut M, Fortunato M, Pea F, Baraldo M (1997) Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa\u2013carbidopa association. Pharmacol Res 35:313\u2013315","journal-title":"Pharmacol Res"},{"key":"614_CR3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.brainres.2005.12.073","volume":"1075","author":"G Chandra","year":"2006","unstructured":"Chandra G, Gangopadhyay PK, Senthil Kumar KS, Mohanakumar KP (2006) Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague\u2013Dawley rats. Brain Res 1075:81\u201392","journal-title":"Brain Res"},{"key":"614_CR4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0014-5793(89)81391-2","volume":"247","author":"Y Furukawa","year":"1989","unstructured":"Furukawa Y, Tomioka N, Sato W, Satoyoshi E, Hayashi K, Furukawa S (1989) Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells. FEBS Lett 247:463\u2013467","journal-title":"FEBS Lett"},{"key":"614_CR5","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1373\/clinchem.2006.074302","volume":"52","author":"GL Hortin","year":"2006","unstructured":"Hortin GL, Seam N, Hoehn GT (2006) Bound homocysteine, cysteine, and cysteinylglycine distribution between albumin and globulins. Clin Chem 52:2258\u20132264","journal-title":"Clin Chem"},{"key":"614_CR6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/WNR.0b013e3282aaa0b4","volume":"18","author":"K Imamura","year":"2007","unstructured":"Imamura K, Takeshima T, Nakaso K, Nakashima K (2007) Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. Neuroreport 18:1319\u20131322","journal-title":"Neuroreport"},{"key":"614_CR7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuro.2005.01.008","volume":"26","author":"ES Lee","year":"2005","unstructured":"Lee ES, Chen H, Soliman KF, Charlton CG (2005) Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26:361\u2013371","journal-title":"Neurotoxicology"},{"key":"614_CR8","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/mds.22807","volume":"24","author":"D Manca","year":"2009","unstructured":"Manca D, Cossu G, Murgia D, Molari A, Ferrigno P, Marcia E, Melis M (2009) Reversible encephalopathy and axonal neuropathy in Parkinson\u2019s disease during duodopa therapy. Mov Disord 24:2293\u20132294","journal-title":"Mov Disord"},{"key":"614_CR9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.21800","volume":"23","author":"B Meiler","year":"2008","unstructured":"Meiler B, Andrich J, M\u00fcller T (2008) Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Mov Disord 23:145\u2013146","journal-title":"Mov Disord"},{"key":"614_CR10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1586\/14737175.8.6.957","volume":"8","author":"T M\u00fcller","year":"2008","unstructured":"M\u00fcller T (2008) Role of homocysteine in the treatment of Parkinson\u2019s disease. Expert Rev Neurother 8:957\u2013967","journal-title":"Expert Rev Neurother"},{"key":"614_CR11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/B978-0-12-381326-8.00004-1","volume":"95","author":"T M\u00fcller","year":"2010","unstructured":"M\u00fcller T (2010) Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-l-methionine and related mechanisms. Int Rev Neurobiol 95:49\u201371","journal-title":"Int Rev Neurobiol"},{"key":"614_CR12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","volume":"62","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller T, Kuhn W (2006) Tolcapone decreases plasma levels of S-adenosyl-l-homocysteine and homocysteine in treated Parkinson\u2019s disease patients. Eur J Clin Pharmacol 62:447\u2013450","journal-title":"Eur J Clin Pharmacol"},{"key":"614_CR13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/mds.22607","volume":"24","author":"T M\u00fcller","year":"2009","unstructured":"M\u00fcller T, Kuhn W (2009) Homocysteine levels after acute levodopa intake in patients with Parkinson\u2019s disease. Mov Disord 24:1339\u20131343","journal-title":"Mov Disord"},{"key":"614_CR14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.parkreldis.2010.07.012","volume":"16","author":"T M\u00fcller","year":"2010","unstructured":"M\u00fcller T, Muhlack S (2010) Acute homocysteine rise after repeated levodopa application in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 16:688\u2013689","journal-title":"Parkinsonism Relat Disord"},{"key":"614_CR15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneur.61.5.657","volume":"61","author":"T M\u00fcller","year":"2004","unstructured":"M\u00fcller T, Renger K, Kuhn W (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61:657\u2013660","journal-title":"Arch Neurol"},{"key":"614_CR16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.wnf.0000183447.58529.79","volume":"28","author":"T M\u00fcller","year":"2005","unstructured":"M\u00fcller T, Lang UE, Muhlack S, Welnic J, Hellweg R (2005) Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease. Clin Neuropharmacol 28:238\u2013240","journal-title":"Clin Neuropharmacol"},{"key":"614_CR17","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00702-006-0442-5","volume":"113","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D (2006) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa\/carbidopa with and without entacapone in patients with Parkinson\u2019s disease. J Neural Transm 113:1441\u20131448","journal-title":"J Neural Transm"},{"key":"614_CR18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216\u2013223","journal-title":"Neurology"},{"key":"614_CR19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.61.6.865","volume":"61","author":"PE O\u2019Suilleabhain","year":"2004","unstructured":"O\u2019Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T, az-Arrastia R (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61:865\u2013868","journal-title":"Arch Neurol"},{"key":"614_CR20","doi-asserted-by":"crossref","unstructured":"Onofrj M, Bonanni L, Cossu G, Manca D, Stocchi F, Thomas A (2009) Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during l-dopa gel treatment. Parkinsonism Relat Disord 15(Suppl 3): S233\u2013S236","DOI":"10.1016\/S1353-8020(09)70821-1"},{"key":"614_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.60.1.59","volume":"60","author":"JD Rogers","year":"2003","unstructured":"Rogers JD, Sanchez-Saffon A, Frol AB, az-Arrastia R (2003) Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60:59\u201364","journal-title":"Arch Neurol"},{"key":"614_CR22","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/mds.22137","volume":"23","author":"C Toth","year":"2008","unstructured":"Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D (2008) Neuropathy as a potential complication of levodopa use in Parkinson\u2019s disease. Mov Disord 23:1850\u20131859","journal-title":"Mov Disord"},{"key":"614_CR23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ana.22021","volume":"68","author":"C Toth","year":"2010","unstructured":"Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, Wiebe S, Zochodne DW, Suchowersky O (2010a) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 68:28\u201336","journal-title":"Ann Neurol"},{"key":"614_CR24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/mds.22879","volume":"25","author":"C Toth","year":"2010","unstructured":"Toth C, Suchowersky O, Zochodne D (2010b) Reply: neuropathy as a potential complication of levodopa use in Parkinson\u2019s disease: a pharmacological and pharmacovigilance point of view. Mov Disord 25:525","journal-title":"Mov Disord"},{"key":"614_CR25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/jnr.10314","volume":"69","author":"WQ Zhao","year":"2002","unstructured":"Zhao WQ, Williams Z, Shepherd KR, Reuben JS, Lee ES, rling-Reed S, Lamango N, Soliman KF, Charlton CG (2002) S-adenosyl-methionine-induced apoptosis in PC12 cells. J Neurosci Res 69:519\u2013529","journal-title":"J Neurosci Res"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-011-0614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-011-0614-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-011-0614-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T22:05:20Z","timestamp":1560031520000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-011-0614-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,27]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1007\/s00702-011-0614-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,27]]}}}